Experimental Cell Therapy for Retinal Degeneration
Part of Eyes & vision, Genetic & congenital clinical trials.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosed with geographic atrophy, Stargardt disease, or similar retinal pigment epithelium degeneration
- Vision within acceptable range for the study
- Eye condition stable before starting the trial
- Healthy enough for eye surgery and anesthesia
- Willing to attend follow-up visits and comply with study instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
This trial tests a single injection of a new medicine, RTx-021, into the eye for people with Stargardt disease. The goal is to see if it is safe and to find the right dose.
This Phase 2 study tests OpRegen, a treatment delivered during special eye surgery, for geographic atrophy related to age-related macular degeneration (GA from AMD). It also includes an imaging “substudy” that uses detailed pictures of your retina to better track safety and activity.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This trial tests if using your own stem cells to create retinal cells can help treat advanced age-related macular degeneration (AMD). If you have severe vision loss from AMD, this approach may restore some sight.
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
Hear when a new Geographic Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.